Clearance of amyloid‐beta with bispecific antibody constructs bound to erythrocytes

We propose use of bispecific monoclonal antibody (mAb) complexes bound to erythrocytes to redress the lack of efficacy of anti‐amyloid beta mAbs in Alzheimer's disease treatment. Our paradigm leverages erythrocyte complement receptor 1 to promote rapid and quantitative removal of amyloid beta f...

Descripción completa

Detalles Bibliográficos
Autores principales: Taylor, Ronald P., Lindorfer, Margaret A., Atkinson, John P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Perspectives
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7453147/
https://www.ncbi.nlm.nih.gov/pubmed/32885023
http://dx.doi.org/10.1002/trc2.12067
_version_ 1783575300792123392
author Taylor, Ronald P.
Lindorfer, Margaret A.
Atkinson, John P.
author_facet Taylor, Ronald P.
Lindorfer, Margaret A.
Atkinson, John P.
author_sort Taylor, Ronald P.
collection PubMed
description We propose use of bispecific monoclonal antibody (mAb) complexes bound to erythrocytes to redress the lack of efficacy of anti‐amyloid beta mAbs in Alzheimer's disease treatment. Our paradigm leverages erythrocyte complement receptor 1 to promote rapid and quantitative removal of amyloid beta from the circulation, and its subsequent removal from the brain as well.
format Online
Article
Text
id pubmed-7453147
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-74531472020-09-02 Clearance of amyloid‐beta with bispecific antibody constructs bound to erythrocytes Taylor, Ronald P. Lindorfer, Margaret A. Atkinson, John P. Alzheimers Dement (N Y) Perspectives We propose use of bispecific monoclonal antibody (mAb) complexes bound to erythrocytes to redress the lack of efficacy of anti‐amyloid beta mAbs in Alzheimer's disease treatment. Our paradigm leverages erythrocyte complement receptor 1 to promote rapid and quantitative removal of amyloid beta from the circulation, and its subsequent removal from the brain as well. John Wiley and Sons Inc. 2020-08-27 /pmc/articles/PMC7453147/ /pubmed/32885023 http://dx.doi.org/10.1002/trc2.12067 Text en © 2020 The Authors. Alzheimer's & Dementia: Translational Research & Clinical Interventions published by Wiley Periodicals LLC on behalf of Alzheimer's Association This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Perspectives
Taylor, Ronald P.
Lindorfer, Margaret A.
Atkinson, John P.
Clearance of amyloid‐beta with bispecific antibody constructs bound to erythrocytes
title Clearance of amyloid‐beta with bispecific antibody constructs bound to erythrocytes
title_full Clearance of amyloid‐beta with bispecific antibody constructs bound to erythrocytes
title_fullStr Clearance of amyloid‐beta with bispecific antibody constructs bound to erythrocytes
title_full_unstemmed Clearance of amyloid‐beta with bispecific antibody constructs bound to erythrocytes
title_short Clearance of amyloid‐beta with bispecific antibody constructs bound to erythrocytes
title_sort clearance of amyloid‐beta with bispecific antibody constructs bound to erythrocytes
topic Perspectives
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7453147/
https://www.ncbi.nlm.nih.gov/pubmed/32885023
http://dx.doi.org/10.1002/trc2.12067
work_keys_str_mv AT taylorronaldp clearanceofamyloidbetawithbispecificantibodyconstructsboundtoerythrocytes
AT lindorfermargareta clearanceofamyloidbetawithbispecificantibodyconstructsboundtoerythrocytes
AT atkinsonjohnp clearanceofamyloidbetawithbispecificantibodyconstructsboundtoerythrocytes

Ejemplares similares